Some seeds refuse to die. Date palm seeds recovered from Herod’s Palace near Jerusalem, roughly 2,000 years old, have been ...

Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor and HER2, and is characterized by aggressive progression, therapeutic resistance and limited targeted-treatment ...

Radiation therapy remains one of the most widely deployed weapons in oncology, yet its effectiveness is routinely undermined by a frustrating biological reality: many cancer cells are simply better at ...

IMNN-001 is not recombinant IL-12 cytokine injected into the bloodstream. Instead, it instructs the patient’s own cells to produce IL-12 locally, activating both innate and adaptive immunity and ...

【日程发布】第七届单细胞与空间组学论坛9月15日，浙江大学研究团队在期刊《MedComm》上发表了研究论文，题为“Cooccurrence of Homologous Recombination Deficiency and Mismatch ...

Thanks to the work of Fred Hutch/University of Washington clinical researchers, a big discovery may soon make a “big, big ...

Our core product, senaparib (IMP4297), has already been commercialized, following its approval as 1L maintenance therapy for ...

I have completed a master's degree in a science-related graduate school and work as a researcher at a manufacturer. At "Kenro," I research prospective universities not just by their names or deviation ...

"I want to create figures for a research paper, but I don't know where to start," or "I don't have time to learn specialized software"—these are common concerns heard in medical and life science ...

IMUNON, Inc. announced that the (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 has revi ...

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

IMUNON, Inc. a annoncé que le Comité indépendant de surveillance des données chargé de superviser son étude translationnelle de phase 2 en cours sur la maladie résiduelle minimale ...